TGTX Stock Summary and Trading Ideas (TG Therapeutics | NASDAQ:TGTX)

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics trades on the NASDAQ stock market under the symbol TGTX.

As of November 19, 2024, TGTX stock price climbed to $29.70 with 748,422 million shares trading.

TGTX has a beta of 1.24, meaning it tends to be more sensitive to market movements. TGTX has a correlation of 0.06 to the broad based SPY ETF.

TGTX has a market cap of $4.60 billion. This is considered a Mid Cap stock.

Last quarter TG Therapeutics reported $84 million in Revenue and $.02 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.

In the last 3 years, TGTX traded as high as $36.50 and as low as $3.48.

The top ETF exchange traded funds that TGTX belongs to (by Net Assets): IJR, IWM, VTI, XBI, VB.

TGTX has outperformed the market in the last year with a price return of +146.1% while the SPY ETF gained +32.2%. TGTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +34.5% and +21.9%, respectively, while the SPY returned +6.5% and +3.3%, respectively.

TGTX support price is $28.21 and resistance is $31.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TGTX shares will trade within this expected range on the day.